DxS Announces License Agreement with Wellcome Trust to expand their range of companion diagnostics
Researchers will use the test to determine a patient’s cancer mutation status, which may predict how they respond to cancer therapies. If clinical trials are successful, this could lead to a companion diagnostics to predict response for novel cancer therapies for skin, thyroid and large intestine cancers.
Dr. Stephen Little, CEO of DxS Ltd., said: “With many novel drugs in development for skin, thyroid and colon cancer the potential for this assay is enormous. Through this licensing agreement, we plan to expand the range of biomarker tests to our customers, aiding the treatment of a number of types of cancer.”
Financial details were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.